⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72400 | 0.45 | — | — | |
| SCHEMBL13407 | 0.45 | — | — | |
| SCHEMBL3870589 | 0.43 | — | — | |
| SCHEMBL1292065 | 0.40 | — | — | |
| SCHEMBL10758404 | 0.38 | — | — | |
| SCHEMBL722089 | 0.38 | — | — | |
| Benzoquinone SCHEMBL18103 | 0.35 | — | — | |
| Benzoquinone SCHEMBL5308519 | 0.35 | ALDH1A1 (1.00) | — | |
| SCHEMBL3092227 | 0.35 | — | — | |
| Benzoquinone SCHEMBL3208089 | 0.35 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | THE JOHN HOPKINS UNIVERSITY (US) | 2008-12-18 | — | — | US | claimed |
| WO-2006135545-A2 | A METHOD FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES CHARACTERIZED BY ADMINISTERING AN EP1 RECEPTOR ANTAGONIST | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-12-21 | — | — | WO | claimed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | claimed |
| US-8088802-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100041708-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7629369-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | THE JOHN HOPKINS UNIVERSITY (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2006135545-A2 | A METHOD FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES CHARACTERIZED BY ADMINISTERING AN EP1 RECEPTOR ANTAGONIST | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. | 2006-02-09 | — | — | US | disclosed |
| EP-1612208-A2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |